Table 3.
The clinical trials using niclosamide for cancer therapy.
| Ref | Cancer type | Potential target | Mechanism | Phase |
|---|---|---|---|---|
| NCT05188170 | Acute Myeloid Leukemia | CREB (58) | Inducing apoptosis and cell cycle arrest | Phase 1 |
| NCT04296851 | Familial adenomatous polyposis (FAP) | Axin-GSK3 (37) | inhibition of Wnt pathway and Snail-mediated EMT | Phase 2 |
| NCT03123978 | Metastatic/Recurrent Prostate Carcinoma | IL6-Stat3-AR pathway (46) | overcome enzalutamide resistance and inhibit migration and invasion | Phase 1 |
| NCT02807805 | Metastatic/Recurrent Prostate Carcinoma | androgen receptor variant 7 | synergizes with abiraterone | Phase 2 |
| NCT02687009 | Colon Cancer | Frizzled receptor (36) | Inhibition of Wnt/β-catenin pathway | Phase 1 |
| NCT02532114 | Castration-Resistant Prostate Carcinoma | Inhibition of androgen receptor splice variants or Wnt/β-catenin pathway (156) | Phase 1 | |
| NCT02519582 | Colorectal Cancer | Wnt/β-catenin pathway signaling (157) | restricting S100A4-driven metastasis | Phase 2 |